Individual risk factors of the metabolic syndrome in adult patients with growth hormone deficiency--a cross-sectional case-control study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

However, there are still a limited number of studies comparing directly the MS prevalence in GHD patients to that in general population.

The aim of this study was to investigate the individual risk factors of the MS in a cohort of GHD patients and to compare its prevalence with an age- and sex-matched control group.

Who Took Part

According to the abstract, 54 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

GHD was diagnosed according to the Endocrine Society Clinical Practice Guideline recommendations from 2011 and MS was scored by the NCEP-ATP III definition.

What Was Measured

The subject headings attached to it are Age of Onset, Blood Pressure, Case-Control Studies, Cholesterol, HDL, Cross-Sectional Studies, Human Growth Hormone and Metabolic Syndrome.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 54 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.